Part-Time
Staff Accountant
Part-Time
Target RWE
51-200 employees
Provides real-world evidence data and consulting
No salary listed
Research Triangle, Durham, NC, USA
Hybrid
Hybrid schedule: 3 days per week in office in RTP.
 Accounting (1) |
|---|
- Bachelor’s degree in accounting, finance, or a related field
- 1-2 years hands-on accounting experience preferred, with demonstrated exposure to accounts payable, accounts receivable, and general ledger functions
- Process and code vendor invoices accurately and in a timely manner within Bill.com
- Manage the full accounts payable cycle from invoice receipt through payment execution
- Administer the employee expense reimbursement program using Concur Time and Expense, ensuring compliance with company policy
- Reconcile accounts payable subledger to the general ledger on a monthly basis
- Maintain vendor records and support annual 1099 filing
- Generate and issue client invoices in accordance with contract terms and project milestones
- Monitor accounts receivable aging and proactively follow up on outstanding balances
- Apply cash receipts and reconcile the accounts receivable subledger to the general ledger monthly
- Partner with project delivery teams to resolve billing discrepancies
- Perform daily and monthly bank reconciliations for all company accounts
- Investigate and resolve reconciling items in a timely manner
- Prepare and post monthly journal entries, including accruals and prepaid amortization
- Support the monthly and annual financial close process
- Assist with audit preparation and provide documentation as requested
- Maintain organized and audit-ready workpapers and account reconciliations
- Identify opportunities to improve accounting processes and system utilization
- Support ad hoc finance projects and reporting as assigned by the Head of Finance
- Experience with Nexonia, Concur, Bill.com, and Sage Intacct
- Motivated self-starter who thrives with consistency and clear day-to-day expectations
- Experience in a professional work environment
- Familiarity with ASC 606 revenue recognition concepts
Target RWE designs and sponsors real-world evidence communities that gather large, disease-specific patient cohorts to produce regulatory-grade data. These data and insights support drug development and regulatory submissions for pharma, regulators, and healthcare providers. They offer custom data solutions, consulting services, and access to biospecimen samples through partnerships and service contracts. Their goal is to enable better regulatory decisions and more efficient drug development by providing high-quality real-world evidence and related services.
Company Size
51-200
Company Stage
Seed
Total Funding
$2.8M
Headquarters
Durham, North Carolina
Founded
2015
Simplify's Take
What believers are saying
- Highlander Health acquisition fuels scaling via leadership hires like Steve Swanson.
- TARGET-NASH surpasses 37,000 patients, enabling 74-month median follow-up insights.
- Syndicated Science Insights tools integrate EMR, PRO, and biospecimens innovatively.
What critics are saying
- Flatiron Health's oncology datasets outcompete TARGET-NASH's smaller cohorts.
- EMA 2025 framework disqualifies US-heavy TARGET-NASH from EU approvals.
- TriNetX's 150 million records render Target RWE's biorepository obsolete.
What makes Target RWE unique
- Target RWE builds disease-specific cohorts like TARGET-NASH with 37,000 patients.
- Precision Medicine Platform offers 150,000 biospecimens from 10,000 patients.
- 'Engage' platform captures patient-reported outcomes for regulatory-grade RWE.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Target RWE who can refer or advise you
Benefits
Hybrid Work Options
Comprehensive health, dental, and vision for you and your family
401(k) with company match
Generous PTO and company holidays
Paid parental leave
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -3%2 year growth
↓ -3%Target RWE, a clinical evidence generation company, has announced three senior leadership appointments to support its growth. Steve Swanson has been promoted to chief commercial officer, leading commercial strategy and partnerships with biopharma and healthcare companies. Emily Akin joins as head of delivery, overseeing clinical operations and data curation. She previously led Flatiron Trials and Research Network at Flatiron Health. Ashley Pierce has been appointed head of finance, bringing experience from Syneos Health and Capitol Broadcasting Company. The company, backed by investment firm Highlander Health, specialises in real-world evidence generation designed to meet regulatory standards for drug development. The leadership team collectively brings nearly 70 years of experience across life sciences and healthcare to advance Target RWE's evidence generation and clinical trial capabilities.
Target RWE announces upcoming presentations at AASLD - The Liver Meeting 2025. DURHAM, N.C.-(BUSINESS WIRE)-Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced it will have multiple presentations focused on the testing and related outcomes of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting(R) 2025, taking place November 7-11, 2025 in Washington, D.C. Poster Number: 2114 Date and Time: November 8, 2025, 8:00 am - 5:00 pm ET Presentation Title: Changes in the Fibrosis-4 (FIB-4) score accurately reflects the disease trajectory of metabolic dysfunction associated steatotic liver disease. Presenter: Vinay Jahagirdar, MD, GI Fellow, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University Health System, Richmond, Virginia. Summary: A FIB-4 score of 1.3-2.6 reflects an intermediate risk stratum of MASLD where secondary tests with vibration-controlled transient elastography (VCTE) repeat testing is recommended. VCTE is not, however, universally available and the utility of repeat FIB-4 testing to assess changes in clinical status in MASLD is not known. The study authors hypothesized that changes in FIB-4 will coordinately track the risk of clinical outcomes in MASLD. The aim of this study was to define the performance of changes in FIB-4 as a disease-monitoring test in MASLD. The authors concluded that changes in FIB-4 predict future risk of adverse health outcomes independent of age and changes in BMI. Thus, in this intermediate risk FIB-4 category especially with T2DM, repeat testing and change in FIB-4 can be used to assess prognosis and disease trajectory. Poster Number: 2618 Date and Time: November 8, 2025, 8:00 am - 5:00 pm ET Presentation Title: Clinical characteristics and outcomes of patients with presumed MASLD who meet MetALD criteria in the TARGET-NASH cohort Presenter: A. Sidney Barritt IV, MD, MSCR, Professor of Medicine, Director of Hepatology, and Transplant Hepatology Program Director in the Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill. Summary: Many patients with hepatic steatosis are presumed to have MASLD due to comorbid cardiovascular (CV) risk factors. However, alcohol use may not be accurately quantified by providers or fully disclosed by some patients. The characteristics and outcomes of patients with MASLD and increased alcohol intake - metabolic dysfunction and alcohol-related liver disease (MetALD) - are unknown. The study sought to describe these patients in the TARGET-NASH cohort and found that despite younger age and fewer metabolic risk factors, MetALD patients suffered a similar number of incident, major adverse cardiovascular(MACE) events on a faster timeframe compared with traditional MASLD patients. About Target RWE Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy. Visit our website to learn more: https://targetrwe.com/
Target RWE unveiled findings on MASH and HCC and contributed expert leadership to the highly anticipated PBC Consensus Conference on May 6th.
Insights into Hidradenitis Suppurativa from Target RWE Featured in Posters at AAD 2025 DURHAM, N.C., March 7, 2025 /PRNewswire/ -- Real-world evidence (RWE) leader, Target RWE, announced updates from its longitudinal dermatology study of more than 7,000 enrolled patients with two poster presentations on patients with Hidradenitis Suppurativa (HS) at the American Academy of Dermatology (AAD) annual meeting in Orlando, FL, March 7-11, 2025
Highlander Health today announced the acquisition of Target RWE from existing investors, including 22C Capital.